AGARWALEYENSEDR AGARWALS HEALTH CARE LLowNeutral
Announced Tue, 14 Jul · 12:27 IST

Dr. Agarwal's Health Care Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Ownership Changes View source PDF

AGARWALEYE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.0%1-day move
₹497.90
prior close
₹488.40
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2-0.2-0.1+0.1-1.0-1.6-1.5-2.1-2.4-3.8
Up moveDown movePending
AI summary

All promoters and promoter group entities of Dr. Agarwal's Health Care — including Dr. Amar Agarwal, Dr. Anosh Agarwal, Dr. Ashar Agarwal, Dr. Ashvin Agarwal, Dr. Adil Agarwal, Dr. Athiya Agarwal, their respective family trusts, and Dr. Agarwal's Eye Institute (partnership and private limited) — have filed the annual Regulation 31(4) declaration with BSE and NSE. Each one confirms that they, along with persons acting in concert, have not created any new encumbrance (pledge, lien, or similar charge) on their equity shares in the company beyond what was already disclosed during FY 2025–26. The filings were digitally signed on April 6, 2026, and are routine annual compliance submissions required by SEBI's takeover regulations.

Likely market impact

This is a routine compliance filing with no material impact on the stock. It simply confirms promoters have not newly pledged or encumbered their holdings, which is mildly reassuring for shareholders as it indicates no sudden fundraising or margin pressure at the promoter level.